Prothena (NASDAQ:PRTA - Get Free Report)'s stock had its "underperform" rating reaffirmed by equities research analysts at Bank of America in a research note issued to investors on Wednesday, May 28th, Marketbeat reports.
PRTA has been the topic of several other reports. Jefferies Financial Group lowered Prothena from a "buy" rating to a "hold" rating and set a $6.00 target price on the stock. in a report on Tuesday, May 27th. JMP Securities lowered their price target on Prothena from $78.00 to $29.00 and set a "market outperform" rating on the stock in a research note on Tuesday, May 27th. Cantor Fitzgerald lowered Prothena from an "overweight" rating to a "neutral" rating in a report on Tuesday, May 27th. HC Wainwright decreased their price target on shares of Prothena from $30.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 27th. Finally, Oppenheimer lowered shares of Prothena from an "outperform" rating to a "market perform" rating in a research report on Tuesday, May 27th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $31.50.
Check Out Our Latest Stock Analysis on Prothena
Prothena Trading Up 1.0%
PRTA traded up $0.05 during trading hours on Wednesday, hitting $4.88. The company's stock had a trading volume of 1,140,960 shares, compared to its average volume of 697,851. The company has a 50-day simple moving average of $8.54 and a 200 day simple moving average of $12.31. The firm has a market capitalization of $262.68 million, a PE ratio of -2.12 and a beta of 0.11. Prothena has a fifty-two week low of $4.32 and a fifty-two week high of $25.42.
Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $8.18 million. During the same quarter in the prior year, the firm earned ($1.34) earnings per share. Prothena's revenue for the quarter was up 5500.0% compared to the same quarter last year. Research analysts expect that Prothena will post -4.04 earnings per share for the current fiscal year.
Institutional Trading of Prothena
Several institutional investors and hedge funds have recently modified their holdings of PRTA. Wellington Management Group LLP boosted its stake in shares of Prothena by 22.8% during the fourth quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company's stock valued at $71,063,000 after purchasing an additional 952,088 shares in the last quarter. Boxer Capital Management LLC acquired a new position in Prothena in the 4th quarter valued at approximately $9,556,000. Federated Hermes Inc. raised its stake in shares of Prothena by 84.3% during the fourth quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company's stock valued at $10,335,000 after acquiring an additional 341,274 shares during the last quarter. Finepoint Capital LP raised its stake in shares of Prothena by 51.6% during the fourth quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company's stock valued at $9,100,000 after acquiring an additional 223,600 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Prothena by 93.7% during the fourth quarter. JPMorgan Chase & Co. now owns 387,350 shares of the biotechnology company's stock worth $5,365,000 after purchasing an additional 187,364 shares during the period. 97.08% of the stock is currently owned by institutional investors.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Read More
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
